Showing results (81-90 of 93) with videos related to
Sort By:
Pageof 10
Journal of Medicinal Chemistry|August 9, 2002
Identification of orally active, potent, and selective 4-piperazinylquinazolines as antagonists of the platelet-derived growth factor receptor tyrosine kinase familyAnjali Pandey, Deborah L Volkots, Joseph M Seroogy, et al.Bioorganic & Medicinal Chemistry Letters|March 23, 2002
Spirocyclic nonpeptide glycoprotein IIb-IIIa antagonists. Part 3: synthesis and SAR of potent and specific 2,8-diazaspiro[4.5]decanesMukund M Mehrotra, Julie A Heath, Jack W Rose, et al.The Journal of Pharmacology and Experimental Therapeutics|November 2, 2011
Specific inhibition of spleen tyrosine kinase suppresses leukocyte immune function and inflammation in animal models of rheumatoid arthritisGreg Coffey, Francis DeGuzman, Mayuko Inagaki, et al.Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|October 19, 2018
Cerdulatinib Pharmacodynamics and Relationships to Tumor Response Following Oral Dosing in Patients with Relapsed/Refractory B-cell MalignanciesGreg P Coffey, Jiajia Feng, Andreas Betz, et al.The Journal of Pharmacology and Experimental Therapeutics|December 11, 2012
The selective SYK inhibitor P505-15 (PRT062607) inhibits B cell signaling and function in vitro and in vivo and augments the activity of fludarabine in chronic lymphocytic leukemiaStephen E Spurgeon, Greg Coffey, Luke B Fletcher, et al.Nature|December 11, 2012
High-resolution crystal structure of human protease-activated receptor 1Cheng Zhang, Yoga Srinivasan, Daniel H Arlow, et al.Journal of Medicinal Chemistry|April 2, 2004
Discovery of novel 2,8-diazaspiro[4.5]decanes as orally active glycoprotein IIb-IIIa antagonistsMukund M Mehrotra, Julie A Heath, Mark S Smyth, et al.Journal of Medicinal Chemistry|June 28, 2002
Potent and selective inhibitors of platelet-derived growth factor receptor phosphorylation. 1. Synthesis, structure-activity relationship, and biological effects of a new class of quinazoline derivativesKenji Matsuno, Michio Ichimura, Takao Nakajima, et al.Blood|September 2, 2011
Critical role for Syk in responses to vascular injuryPatrick Andre, Toshifumi Morooka, Derek Sim, et al.Cancer Cell|July 19, 2002
CT53518, a novel selective FLT3 antagonist for the treatment of acute myelogenous leukemia (AML)Louise M Kelly, Jin-Chen Yu, Christina L Boulton, et al.Pageof 10